5-fluorouracil resistant advanced and recurrent Gastric Cancer
Conditions
Interventions
TXL 140mg/m2/week iv, day1.15 q 4weeks
Sponsors
The Tokyo Cooperative Oncology Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) With pathologically proven gastric cancer 2) ECOG performance status of 0-2 3) With at least one measurable lesion (RECIST) 4)Cases with previous treatment containing 5- fluorouracil, and was refractory or recurrent (limited to only 1 course and the interval was required for more than 2 weeks) 5) With adequate bone marrow, cardiac, respiratory, hepatic, and renal functions. 6) No Accompanied serious diseases, No Active secondary cancer 7) Age 20-80 years 8) With written informed consent
Exclusion criteria
Exclusion criteria: 1) Accompanied serious diseases 2) A past history of drug allergy 3) A past history of allergic reaction to polyoxy-ethilen oil 4) Acute inflammatory disease 5) Peripheral neuropathy 6) Pregnancy or breast feeding 7) Concomitant malignancy. It influences survival, adverse events 8) Symptomatic brain metastasis 9) hypersensitivity to alcohol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response Rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events, OS, TTP | — |
Countries
Japan
Outcome results
None listed